))
AI is Not Sci-Fi: The Potential of Artificial Intelligence in Drug Discovery
Manage episode 353582105 series 3310882
Content provided by Danish Diabetes and Endocrine Academy, Danish Diabetes, and Endocrine Academy. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Danish Diabetes and Endocrine Academy, Danish Diabetes, and Endocrine Academy or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
AI is dramatically changing the landscape of drug discovery in research today, but what is needed for the best outcomes? How do we overcome the challenges?
Artificial intelligence is not the future anymore; it is happening now – and it is happening on a grand scale.
Academic researchers and pharmaceutical companies have started utilising AI to aid in drug discovery. Drug discovery is a lengthy and costly process, with average research and development for new drugs taking 10-20 years and costing billions of dollars. New approaches are needed, and looking to AI might unlock potential that we have not yet imagined. But are there costs?
Listen as an expert in AI and machine learning and an experimental biologist discuss the evolution, applications of AI and its possible uses in medical research.
Guests:
Per Greisen, Director of Computational Drug Discovery at Novo Nordisk.
Hande Topel, Postdoctoral researcher in a functional genomics and metabolism unit at the University of Southern Denmark
Host:
Gretchen Repasky, Communications Director, Nordic EMBL Partnership for Molecular Medicine and the University of Helsinki.
Publisher:
Danish Diabetes and Endocrine Academy
Producer:
Kontekst & Lyd
You can find additional information about the podcast at www.ddeacademy.dk/podcasts
19 episodes
Share
